Novo Nordisk was a pioneer in developing GLP-1 drugs ... The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk remains a sell due to increased competition ... which were labeled as close to patent expiration in the 2023 20-F filing. These two drugs contributed to Novo's sales, but as can ...

Novo Nordisk and Ascendis Pharma have agreed to ... As per the deal signed yesterday (4 November), the two Danish companies will jointly develop therapeutics for metabolic and cardiovascular ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity ... has been on the shortage list for over two years, with different doses being listed in shortage at various times.

As you can see from the chart above the percentage of shares that are sold short for Novo Nordisk has declined since its last report. This does not mean that the stock is going to rise in the near ...

LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations.

The company is due to release data before the end of this year from a late-stage trial of CagriSema, a two-drug combination ... coverage of Danish drugmaker Novo Nordisk and its race to increase ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range. The maker ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...